Angiosarcoma of bone: a retrospective study of the European Musculoskeletal Oncology Society (EMSOS).
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
02 07 2020
02 07 2020
Historique:
received:
15
10
2019
accepted:
13
05
2020
entrez:
4
7
2020
pubmed:
4
7
2020
medline:
16
12
2020
Statut:
epublish
Résumé
Angiosarcoma of bone (B-AS) is a rare malignant tumor of vascular origin. The aim of this retrospective study is to report on treatments and prognosis. Data were collected from the EMSOS website. 80 patients in 9 centers included: 51 male/29 female; median age 54 years (range 17 to 92); 56% with localized disease, 44% metastatic. Primary tumor surgery: 76% (30% amputation, 26% intralesional margins); radiotherapy (RT): 41%; chemotherapy (CT): 47% (56% in metastatic, 41% in localized cases). With a median follow-up of 31 months (range 40 to 309), 5-year overall survival (OS) was 27% (95%CI 16-30): 41% (95%CI 25-56) for localized patients, and 8% (95%CI 0-20) for metastatic (p = 0.002). In metastatic patients, 1 year OS was significantly influenced by chemotherapy response: 67% (95CI% 29-100) for those who responded or had stable disease (n = 7), and 18% (95CI% 0-41) for patients with progressive disease (n = 11), p 0.002. The surgical complete remission (SCR) status was pivotal in localized patients (5-year OS 45% for SCR, 17% no SCR, p = 0.03); also 5-year OS was significantly influenced by age and site of the tumor. After multivariate analysis, the addition of radiotherapy to surgery significantly influenced the disease-free survival (DFS) rate, whereas the use of chemotherapy lost the significance showed at the univariate analysis. Overall, patients with metastatic B-AS have a dismal prognosis, with a prolonged survival in case with a response to chemotherapy. Experimental trials with more active systemic treatment regimens are needed. In patients with localized disease, the patient's age and site of the tumor are prognostic factors and any effort must be made to achieve an SCR status. No definitive conclusions can be drawn from our data on the use of adjuvant chemotherapy, while the use of adjuvant radiotherapy might improve DSF in patients surgically free of disease.
Identifiants
pubmed: 32616718
doi: 10.1038/s41598-020-66579-5
pii: 10.1038/s41598-020-66579-5
pmc: PMC7331738
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10853Références
Bovée, J. V. & Rosenberg, A. E. Angiosarcoma. In Pathology and genetics of tumours of soft tissue and bone. World Health Organization Classification of Tumours, 4th ed. (eds. Fletcher C. D. M. & Bridge J. A.) 337–338 (International Agency for Research on Cancer (IARC) Press, Lyon 2013).
Wenger, D. E. & Wold, L. E. Malignant vascular lesions of bone: radiologic and pathologic features. Skeletal Radiol. 29, 619–631 (2000).
doi: 10.1007/s002560000261
Evans, H. L., Raymond, A. K. & Ayala, A. G. Vascular tumors of bone: A study of 17 cases other than ordinary hemangioma, with an evaluation of the relationship of hemangioendothelioma of bone to epithelioid hemangioma, epithelioid hemangioendothelioma, and high-grade angiosarcoma. Hum. Pathol. 34, 680–689 (2003).
doi: 10.1016/S0046-8177(03)00249-1
Verbeke, S. L. J. et al. Distinct Histologic Features Characterize Primary Angiosarcoma of Bone. Histopathology 58, 254–264 (2011).
doi: 10.1111/j.1365-2559.2011.03750.x
Mirra, J. M. Angiosarcoma of bone: solitary and multifocal variants. In Bone tumours. Clinical, radiologic and pathologic correlations. (ed. Mirra, J. M.) 1382–1417 (Philadelphia: Lea and Febiger 1989).
Deshpande, V., Rosenberg, A. E., O’Connell, J. X. & Nielsen, G. P. Epithelioid angiosarcoma of the bone: a series of 10 cases. Am. J. Surg. Pathol. 27, 709–716 (2003).
doi: 10.1097/00000478-200306000-00001
Fayette, J. et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann. Oncol. 18, 2030–2036 (2007).
doi: 10.1093/annonc/mdm381
Palmerini, E. et al. Primary angiosarcoma of bone: a retrospective analysis of 60 patients from two institutions. Am. J. Clin. Oncol. 37, 528–34 (2014).
doi: 10.1097/COC.0b013e31827defa1
Redondo, A. S. et al. Malignant bone tumors (other than Ewing’s): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS). Cancer Chemother Pharmacol. 80, 1113–1131 (2017).
doi: 10.1007/s00280-017-3436-0
Wold, L. E. et al. Hemangioendothelial sarcoma of bone. Am. J. Surg. Pathol. 6, 59–70 (1982).
doi: 10.1097/00000478-198201000-00006
Unni, K. K., Ivins, J. C., Beabout, J. W. & Dahlin, D. C. Hemangioma, hemangiopericytoma, and hemangioendothelioma (angiosarcoma) of bone. Cancer 27, 1403–1414 (1971).
doi: 10.1002/1097-0142(197106)27:6<1403::AID-CNCR2820270621>3.0.CO;2-6
Boriani, S. et al. Primary vascular bone tumors in the spine: a challenge for pathologists and spine oncology surgeons. Eur. Spine J. 28, 1502–1511 (2019).
doi: 10.1007/s00586-019-05930-5
Wang, L., Lao, I. W., Yu, L. & Wang, J. Clinicopathological features and prognostic factors in angiosarcoma: a retrospective analysis of 200 patients from a single Chinese medical institute. Oncol. Lett. 14, 5370–5378 (2017).
pubmed: 29113171
pmcid: 5656021
Verbeke, S. L. J. et al. Array CGH analysis Identifies Two Distinct Subgroups of Primary Angiosarcoma of Bone. Genes Chromosomes Cancer 54, 72–81 (2015).
doi: 10.1002/gcc.22219
Huang, S. C. et al. Recurrent CIC Gene Abnormalities in Angiosarcomas: A Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations. Am. J. Surg. Pathol. 40, 645–55 (2016).
doi: 10.1097/PAS.0000000000000582
Enneking, W. F., Spanier, S. S. & Goodman, M. A. Current concepts review. The surgical staging of musculoskeletal sarcoma. J. Bone Joint Surg. Am. 62, 1027–1030 (1980).
doi: 10.2106/00004623-198062060-00028
Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 45, 228–247 (2009).
doi: 10.1016/j.ejca.2008.10.026
Casali, P. G. et al. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29, iv79–iv95 (2018).
doi: 10.1093/annonc/mdy310